The effects of antipsychotics on the brain: What have we learnt from structural imaging of schizophrenia? - A systematic review

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2535-2549

  Smieskova, R ^a   Fusar Poli, P ^b   Allen, P ^a   Bendfeldt, K ^a   Stieglitz, R D ^a   Drewe, J ^a   Radue, E W ^a   McGuire, P K ^a   Riecher Rossler A ^a   Borgwardt, S J ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Atypical neuroleptics; Conventional; MRI; Neuroimaging; Schizophrenia; Typical

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ADOLESCENT ONSET SCHIZOPHRENIA; BASAL GANGLION; BRAIN FOURTH VENTRICLE; BRAIN SIZE; CAUDATE NUCLEUS; CEREBELLUM VERMIS; CEREBROSPINAL FLUID; CHILDHOOD ONSET SCHIZOPHRENIA; CHRONIC PATIENT; CINGULATE GYRUS; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPOPHYSIS; INSULA; LONGITUDINAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; THALAMUS;

ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA;

EID: 67649876638     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957456     Document Type: Review

References (99)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4(11): 1241-3.
2. Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, et al. Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments. Cereb Cortex. 2008; Epub ahead of print.
3. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998; 155(12): 1711-7.
4. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: A meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005; 162(12): 2233-45.
5. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 1975; 72(11): 4376-80.
6. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978; 135(2): 165-73.
7. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, et al. Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60(3): 358-403.
8. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(7): 1159-72.
9. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49(1-2): 1-52.
10. Wright P, Nimgaonkar VL, Donaldson PT, Murray RM. Schizophrenia and HLA: a review. Schizophr Res 2001; 47(1): 1-12.
11. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998; 172: 110-20.
12. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157(1): 16-25.
13. Lawrie SM, Whalley H, Kestelman JN, Abukmeil SS, Byrne M, Hodges A, et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 1999; 353(9146): 30-3.
14. Gur RE, Keshavan MS, Lawrie SM. Deconstructing psychosis with human brain imaging. Schizophr Bull 2007; 33(4): 921-31.
15. Harrison PJ, Freemantle N, Geddes JR. Meta-analysis of brain weight in schizophrenia. Schizophr Res 2003; 64(1): 25-34.
16. Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res 1999; 40(2): 87-99.
17. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001; 50(10): 729-42.
18. Scherk H, Falkai P. Effects of antipsychotics on brain structure. Curr Opin Psychiatry 2006; 19(2): 145-50.
19. Phillips ML, Travis MJ, Fagiolini A, Kupfer DJ. Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 2008; 165(3): 313-20.
20. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 2008; 69 Suppl 4: 21-5.
21. Vita A, De Peri L. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int Rev Psychiatry 2007; 19(4): 429-36.
22. Pressler M, Nopoulos P, Ho BC, Andreasen NC. Insular cortex abnormalities in schizophrenia: Relationship to symptoms and typical neuroleptic exposure. Biol Psychiatry 2005; 57(4): 394-8.
23. Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, et al. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry 2005; 186: 26-31
24. Kopelman A, Andreasen NC, Nopoulos P. Morphology of the anterior cingulate gyrus in patients with schizophrenia: Relationship to typical neuroleptic exposure. Am J Psychiatry 2005; 162(10): 1872-8.
25. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sanchez J, et al. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res 2005; 80(1): 61-71.
26. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry 2005; 58(1): 62-6.
27. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: The AESOP study. Neuropsychopharmacology 2005; 30(4): 765-74.
28. Pariante CM, Dazzan P, Danese A, Morgan KD, Brudaglio F, Morgan C, et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005; 30(10): 1923-31.
29. McClure RK, Phillips I, Jazayerli R, Barnett A, Coppola R, Weinberger DR. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Res 2006; 148(2-3): 121-32.
30. Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res 2004; 130(1): 71-8.
31. Chua SE, Deng Y, Chen EY, Law CW, Chiu CP, Cheung C, et al. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychol Med 2008: 1-8.
32. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62(4): 361-70.
33. McClure RK, Carew K, Greeter S, Maushauer E, Steen G, Weinberger DR. Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment. Schizophr Res 2008; 98(1-3): 29-39.
34. Stip E, Mancini-Marie A, Fahim C, Bentaleb LA, Letourneau G, Potvin S. Decrease in basal ganglia grey matter density associated with atypical antipsychotic treatment in schizophrenia patients. Schizophr Res 2008; 103(1-3): 319-21.
35. Girgis RR, Diwadkar VA, Nutche JJ, Sweeney JA, Keshavan MS, Hardan AY. Risperidone in first-episode psychosis: A longitudinal, exploratory voxel-based morphometric study. Schizophr Res 2006; 82(1): 89-94.
36. Massana G, Salgado-Pineda P, Junque C, Perez M, Baeza I, Pons A, et al. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J Clin Psychopharmacol 2005; 25(2): 111-7.
37. Gogtay N, Sporn A, Clasen LS, Nugent TF, 3rd, Greenstein D, Nicolson R, et al. Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses. Arch Gen Psychiatry 2004; 61(1): 17-22.
38. Frazier JA, Giedd JN, Kaysen D, Albus K, Hamburger S, Alaghband-Rad J, et al. Childhood-onset schizophrenia: Brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 1996; 153(4): 564-6.
39. James AC, James S, Smith DM, Javaloyes A. Cerebellar, prefrontal cortex, and thalamic volumes over two time points in adolescent-onset schizophrenia. Am J Psychiatry 2004; 161(6): 1023-9.
40. Tauscher-Wisniewski S, Tauscher J, Christensen BK, Mikulis DJ, Zipursky RB. Volumetric MRI measurement of caudate nuclei in antipsychotic-naive patients suffering from a first episode of psychosis. J Psychiatr Res 2005; 39(4): 365-70.
41. Tauscher-Wisniewski S, Tauscher J, Logan J, Christensen BK, Mikulis DJ, Zipursky RB. Caudate volume changes in first episode psychosis parallel the effects of normal aging: A 5-year follow-up study. Schizophr Res 2002; 58(2-3): 185-8.
42. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151(10): 1430-6.
43. Heitmiller DR, Nopoulos PC, Andreasen NC. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr Res 2004; 66(2-3): 137-42.
44. Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 2004; 161(10): 1829-36.
45. Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001; 24(1): 47-54.
46. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics. Am J Psychiatry 1999; 156(8): 1200-4.
47. Strungas S, Christensen JD, Holcomb JM, Garver DL. State-related thalamic changes during antipsychotic treatment in schizophrenia: preliminary observations. Psychiatry Res 2003; 124(2): 121-4.
48. McCormick L, Decker L, Nopoulos P, Ho BC, Andreasen N. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr Res 2005; 80(1): 73-84.
49. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: A longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60(6): 585-94.
50. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 1999; 96(23): 13432-7.
51. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Tost H, Henn FA. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur Neuropsychopharmacol 2002; 12(2): 145-52.
52. Honey GD, Fletcher PC, Bullmore ET. Functional brain mapping of psychopathology. J Neurol Neurosurg Psychiatry 2002; 72(4): 432-9.
53. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 2004; 29(1): 171-8.
54. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25(2): 233-55.
55. DeLisi LE. Reviewing the "facts about schizophrenia:: a possible or impossible task? Schizophr Res 2008; 102(1-3): 19-20.
56. Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack HG, van der Linden JA, et al. Brain volume changes in first-episode schizophrenia: A 1-year follow-up study. Arch Gen Psychiatry 2002; 59(11): 1002-10.
57. Kasai K, Shenton ME, Salisbury DF, Onitsuka T, Toner SK, Yurgelun-Todd D, et al. Differences and similarities in insular and temporal pole MRI gray matter volume abnormalities in first-episode schizophrenia and affective psychosis. Arch Gen Psychiatry 2003; 60(11): 1069-77.
58. Kubicki M, Shenton ME, Salisbury DF, Hirayasu Y, Kasai K, Kikinis R, et al. Voxel-based morphometric analysis of gray matter in first episode schizophrenia. Neuroimage 2002; 17(4): 1711-9.
59. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58(2): 148-57.
60. Sporn AL, Greenstein DK, Gogtay N, Jeffries NO, Lenane M, Gochman P, et al. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am J Psychiatry 2003; 160(12): 2181-9
61. Wood SJ, Velakoulis D, Smith DJ, Bond D, Stuart GW, McGorry PD, et al. A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophr Res 2001; 52(1-2): 37-46.
62. Gschwandtner U, Aston J, Borgwardt S, Drewe M, Feinendegen C, Lacher D, et al. Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: Preliminary results from the Basel early detection of psychosis study - Fruherkennung von Psychosen (FEPSY). Acta Psychiatr Scand 2003; 108(2): 152-5.
63. Gschwandtner U, Pfluger M, Aston J, Borgwardt S, Drewe M, Stieglitz RD, et al. Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256(4): 201-6.
64. Riecher-Rossler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, et al. The Basel early-detection-of-psychosis (FEPSY)-study--design and preliminary results. Acta Psychiatr Scand 2007; 115(2): 114-25.
65. Riecher-Rossler A, Gschwandtner U, Borgwardt S, Aston J, Pfluger M, Rossler W. Early detection and treatment of schizophrenia: How early? Acta Psychiatr Scand Suppl 2006(429): 73-80.
66. Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A, Caverzasi E, et al. Neurofunctional correlates of vulnerability to psychosis: A systematic review and meta-analysis. Neurosci Biobehav Rev 2007; 31(4): 465-84.
67. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res 2004; 68(1): 1-9.
68. Baare WF, van Oel CJ, Hulshoff Pol HE, Schnack HG, Durston S, Sitskoorn MM, et al. Volumes of brain structures in twins discordant for schizophrenia. Arch Gen Psychiatry 2001; 58(1): 33-40.
69. Boos HB, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS. Brain volumes in relatives of patients with schizophrenia: A meta-analysis. Arch Gen Psychiatry 2007; 64(3): 297-304.
70. Borgwardt SJ, McGuire P, Fusar-Poli P, Radue EW, Riecher-Rossler A. Anterior cingulate pathology in the prodromal stage of schizophrenia. Neuroimage 2008; 39(2): 553-4.
71. Borgwardt SJ, McGuire PK, Aston J, Berger G, Dazzan P, Gschwandtner U, et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl 2007; 51: S69-75.
72. Borgwardt SJ, Radue EW, Gotz K, Aston J, Drewe M, Gschwandtner U, et al. Radiological findings in individuals at high risk of psychosis. J Neurol Neurosurg Psychiatry 2006; 77(2): 229-33.
73. Borgwardt SJ, Riecher-Rossler A, Dazzan P, Chitnis X, Aston J, Drewe M, et al. Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry 2007; 61(10): 1148-56.
74. Cannon TD, Thompson PM, van Erp TG, Toga AW, Poutanen VP, Huttunen M, et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc Natl Acad Sci USA 2002; 99(5): 3228-33.
75. Haller S, Borgwardt SJ, Schindler C, Aston J, Radue EW, Riecher-Rossler A. Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study. Radiology 2009; 250(1): 212-21.
76. Hulshoff Pol HE, Brans RG, van Haren NE, Schnack HG, Langen M, Baare WF, et al. Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophrenia. Biol Psychiatry 2004; 55(2): 126-30.
77. Keshavan MS, Montrose DM, Pierri JN, Dick EL, Rosenberg D, Talagala L, et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: Preliminary studies. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21(8): 1285-95.
78. Meisenzahl EM, Koutsouleris N, Bottlender R, Scheuerecker J, Jager M, Teipel SJ, et al. Structural brain alterations at different stages of schizophrenia: A voxel-based morphometric study. Schizophr Res 2008; 104(1-3): 44-60.
79. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet 2003; 361(9354): 281-8.
80. Seidman LJ, Faraone SV, Goldstein JM, Goodman JM, Kremen WS, Toomey R, et al. Thalamic and amygdala-hippocampal volume reductions in first-degree relatives of patients with schizophrenia: An MRI-based morphometric analysis. Biol Psychiatry 1999; 46(7): 941-54.
81. Borgwardt SJ, McGuire PK, Aston J, Gschwandtner U, Pfluger MO, Stieglitz RD, et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008; 106(2-3): 108-14.
82. Job DE, Whalley HC, Johnstone EC, Lawrie SM. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage 2005; 25(4): 1023-30.
83. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR. Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role in neurotoxicity and tardive dyskinesia. Brain Res 1998; 788(1-2): 215-22.
84. Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 2008; 63(8): 759-65.
85. Wang HD, Dunnavant FD, Jarman T, Deutch AY. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004; 29(7): 1230-8.
86. Chlan-Fourney J, Ashe P, Nylen K, Juorio AV, Li XM. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002; 954(1): 11-20.
87. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003; 28(1): 1-13.
88. Parikh V, Khan MM, Terry A, Mahadik SP. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J Psychiatr Res 2004; 38(5): 521-9.
89. Selemon LD, Lidow MS, Goldman-Rakic PS. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry 1999; 46(2): 161-72.
90. Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. Dysregulated brain development in adult men with schizophrenia: A magnetic resonance imaging study. Biol Psychiatry 2003; 53(5): 412-21
91. Hof PR, Haroutunian V, Friedrich VL, Jr., Byne W, Buitron C, Perl DP, et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53(12): 1075-85.
92. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001; 14(1 Pt 1): 21-36.
93. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage 2000; 11(6 Pt 1): 805-21.
94. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000; 57(7): 637-48.
95. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006; 81(1): 47-63.
96. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 2004; 372(1-2): 157-60.
97. Cunha, RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008; 14(15): 1512-24.
98. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008; 14(14): 1452-65.
99. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS ONE 2008; 3(9): E3150.